Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Neogen (NEOG)

Neogen says regulatory review of Genomics sale to Zoetis expected to end in early 2027

Neutral Impact 3 of 5 m&a

Neogen said it expects regulatory review of its planned sale of its global Genomics business to Zoetis to conclude in early 2027. The deal, first announced March 2, 2026, remains subject to customary closing conditions and regulatory approvals, and Zoetis has offered to divest certain Australian assets to help clear the review. The filing gives no purchase price or financial impact, so shareholders face a longer timeline before the transaction can close.

Key points

  • Neogen agreed on March 2, 2026 to sell its global Genomics business to Zoetis Inc.
  • The Australian Competition and Consumer Commission and New Zealand Commerce Commission are continuing reviews of the transaction.
  • Zoetis has offered to divest certain assets in Australia to assist the clearance process.
  • Neogen expects regulatory review to conclude in early 2027.

The filing

CompanyNeogen (NEOG)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:00 PM ET
Accession number0001193125-26-447166

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.